Rohan Khera1, Javier Valero-Elizondo2, Sandeep R Das1, Salim S Virani3, Bita A Kash4,5, James A de Lemos1, Harlan M Krumholz2,6,7, Khurram Nasir8. 1. Division of Cardiology, University of Texas Southwestern Medical Center, Dallas (R.K., S.R.D., J.A.d.L.). 2. Center for Outcomes Research and Evaluation, Yale New Haven Health, CT (J.V.-E., H.M.K.). 3. Division of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, TX (S.S.V.). 4. Center for Outcomes Research, Houston Methodist Research Institute, TX (B.A.K.). 5. School of Public Health, Texas A&M University, College Station (B.A.K.). 6. Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT (H.M.K.). 7. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT (H.M.K.). 8. Division of Cardiovascular Prevention and Wellness Houston Methodist DeBakey Heart & Vascular Center & Center for Outcomes Research Houston Methodist, Houston, TX (K.N.).
Abstract
BACKGROUND: Medication nonadherence is associated with worse outcomes in patients with atherosclerotic cardiovascular disease (ASCVD), a group who requires long-term therapy for secondary prevention. It is important to understand to what extent drug costs, which are potentially actionable factors, contribute to medication nonadherence. METHODS: In a nationally representative survey of US adults in the National Health Interview Survey (2013-2017), we identified individuals ≥18 years with a reported history of ASCVD. Participants were considered to have experienced cost-related nonadherence (CRN) if in the preceding 12 months they reported skipping doses to save money, taking less medication to save money, or delaying filling a prescription to save money. We used survey analysis to obtain national estimates. RESULTS: Of the 14 279 surveyed individuals with ASCVD, a weighted 12.6% (or 2.2 million [95% CI, 2.1-2.4]) experienced CRN, including 8.6% or 1.5 million missing doses, 8.8% or 1.6 million taking lower than prescribed doses, and 10.5% or 1.9 million intentionally delaying a medication fill to save costs. Age <65 years, female sex, low family income, lack of health insurance, and high comorbidity burden were independently associated with CRN, with >1 in 5 reporting CRN in these subgroups. Survey respondents with CRN compared with those without CRN had 10.8-fold higher odds of requesting low-cost medications and 8.9-fold higher odds of using alternative, nonprescription, therapies. CONCLUSIONS: One in 8 patients with ASCVD reports nonadherence to medications because of cost. The removal of financial barriers to accessing medications, particularly among vulnerable patient groups, may help improve adherence to essential therapy to reduce ASCVD morbidity and mortality.
BACKGROUND: Medication nonadherence is associated with worse outcomes in patients with atherosclerotic cardiovascular disease (ASCVD), a group who requires long-term therapy for secondary prevention. It is important to understand to what extent drug costs, which are potentially actionable factors, contribute to medication nonadherence. METHODS: In a nationally representative survey of US adults in the National Health Interview Survey (2013-2017), we identified individuals ≥18 years with a reported history of ASCVD. Participants were considered to have experienced cost-related nonadherence (CRN) if in the preceding 12 months they reported skipping doses to save money, taking less medication to save money, or delaying filling a prescription to save money. We used survey analysis to obtain national estimates. RESULTS: Of the 14 279 surveyed individuals with ASCVD, a weighted 12.6% (or 2.2 million [95% CI, 2.1-2.4]) experienced CRN, including 8.6% or 1.5 million missing doses, 8.8% or 1.6 million taking lower than prescribed doses, and 10.5% or 1.9 million intentionally delaying a medication fill to save costs. Age <65 years, female sex, low family income, lack of health insurance, and high comorbidity burden were independently associated with CRN, with >1 in 5 reporting CRN in these subgroups. Survey respondents with CRN compared with those without CRN had 10.8-fold higher odds of requesting low-cost medications and 8.9-fold higher odds of using alternative, nonprescription, therapies. CONCLUSIONS: One in 8 patients with ASCVD reports nonadherence to medications because of cost. The removal of financial barriers to accessing medications, particularly among vulnerable patient groups, may help improve adherence to essential therapy to reduce ASCVD morbidity and mortality.
Entities:
Keywords:
atherosclerosis; cardiovascular disease; costs and cost analysis; medication adherence
Authors: Tianna Zhou; Patrick Liu; Sanket S Dhruva; Nilay D Shah; Reshma Ramachandran; Karina M Berg; Joseph S Ross Journal: JAMA Intern Med Date: 2022-02-01 Impact factor: 44.409
Authors: Mohammad Hashim Jilani; Zulqarnain Javed; Tamer Yahya; Javier Valero-Elizondo; Safi U Khan; Bita Kash; Ron Blankstein; Salim S Virani; Michael J Blaha; Prachi Dubey; Adnan A Hyder; Farhaan S Vahidy; Miguel Cainzos-Achirica; Khurram Nasir Journal: Curr Atheroscler Rep Date: 2021-07-26 Impact factor: 5.113
Authors: Kara E MacLeod; John M Chapel; Matthew McCurdy; Jasmin Minaya-Junca; Diane Wirth; Anekwe Onwuanyi; Rashon I Lane Journal: Health Serv Res Date: 2021-02-12 Impact factor: 3.734
Authors: Riyad Kherallah; Mahmoud Al Rifai; Ishan Kamat; Chayakrit Krittanawong; Dhruv Mahtta; Michelle T Lee; Jing Liu; Khurram Nasir; Javier Valero-Elizondo; Jaideep Patel; Mouaz H Al-Mallah; Laura A Petersen; Salim S Virani Journal: Prev Med Date: 2021-07-07 Impact factor: 4.637
Authors: Amit Khera; Seth J Baum; Ty J Gluckman; Martha Gulati; Seth S Martin; Erin D Michos; Ann Marie Navar; Pam R Taub; Peter P Toth; Salim S Virani; Nathan D Wong; Michael D Shapiro Journal: Am J Prev Cardiol Date: 2020-05-01